After clearing over 1,250 traditional AI medical devices, the agency faces its first test case for large language model technology that talks directly to patients
March 3rd, 2026: RecovryAI emerges from stealth, announces designation publiclyNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
In This Story
A healthcare worker examines a chest X-ray image, focusing on diagnosis.
RecovryAI Announces FDA Breakthrough Device Designation for ...
FDA offers clues to AI regulation with RecovryAI designation ...
Navigating AI in medical devices & healthcare – from hype to ...
Greenlight Guru
The Current State of 950 FDA-Approved AI-based Medical ...
The Medical Futurist
Risks of AI-Controlled Healthcare Devices | #ExpertKeynote ...
Insight Jam
Images from Openverse under Creative Commons licenses. Videos from YouTube.
Exploring all sides of a story is often best achieved with Play.
Fictional AI pastiche — not real quote.
"The machine will ask after your sleep and your diet, and somewhere in an office a committee will decide what counts as a correct answer — which is to say, they have not built a doctor's assistant so much as a very expensive form."
Fictional AI pastiche — not real quote.
"'Tis a curious republic where we trust a machine to enquire after our sleep and digestion, yet spend years debating whether it may do so lawfully — I have known slower progress only in the matter of collecting taxes."
Sign up to generate historical perspectives on this story.
Two rounds, two personas, one winner. You set the crossfire.
Watch two AI personas debate this story using real evidence
Choose one persona for each side of the debate
Select debater for this side:
Select debater for this side:
Make your prediction before the referee scores
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
A startup developing physician-prescribed, patient-facing AI chatbots powered by large language models to guide patients through post-surgical recovery.
The federal agency responsible for authorizing medical devices for sale in the United States, including software classified as a medical device.
A pioneering therapy chatbot company that received Breakthrough Device Designation in 2021 for postpartum depression but shut down its consumer app in 2025, citing the cost of FDA compliance and the agency's inability to regulate LLM-based tools.
RecovryAI publicly announced its Breakthrough Device Designation and revealed its pivotal clinical study at OrthoArizona and Mercy Medical Center in Baltimore, pursuing FDA authorization under a novel Class II pathway for patient-facing Software as a Medical Device.
The FDA granted Breakthrough Device Designation to RecovryAI's Virtual Care Assistants, a patient-facing generative AI chatbot built on large language model technology — the first such designation for a device of this kind.
Woebot Health closed its direct-to-consumer cognitive behavioral therapy chatbot, with the founder citing the cost of FDA requirements and the agency's inability to regulate the large language models the company wanted to adopt.
The FDA rolled out an internal generative AI chatbot built on Anthropic's Claude across all agency centers, using it to help staff read, write, and summarize documents — adopting internally the same class of technology it had not yet authorized for patient use.
The FDA released draft guidance titled 'Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations,' addressing foundation models and LLMs for the first time but stopping short of creating a specific generative AI pathway.
The Centers for Medicare and Medicaid Services added three new billing codes for digital mental health treatment devices, addressing a major reimbursement gap that contributed to earlier digital therapeutics failures.
Akili Interactive, maker of an FDA-authorized prescription video game for attention deficit hyperactivity disorder, abandoned the prescription model and made the product over-the-counter after payer resistance.
Pear Therapeutics, which held FDA clearance for digital therapeutics treating substance use disorders and insomnia, declared bankruptcy after insurers largely refused to cover its products — erasing over $400 million in investment.
The FDA granted Breakthrough Device Designation to Wysa's AI-led conversational agent for chronic musculoskeletal pain with depression and anxiety. Like Woebot, Wysa used scripted dialogue, not generative AI.
Woebot Health received FDA Breakthrough Device Designation for its cognitive behavioral therapy chatbot targeting postpartum depression — a rules-based system, not generative AI.
The FDA released its Artificial Intelligence/Machine Learning Software as a Medical Device Action Plan, outlining how the agency intends to approach AI-enabled devices. The plan introduced the concept of predetermined change control plans, allowing manufacturers to update algorithms after clearance.
Discussed by: STAT News, health technology analysts, FDA regulatory attorneys at firms like King & Spalding and Sidley Austin
RecovryAI completes its pivotal study with results showing its chatbot's behavior aligns with physician judgment. The FDA grants Class II authorization under a De Novo pathway, creating the first predicate device for patient-facing generative AI. This opens the door for other LLM-based medical products to file 510(k) submissions claiming substantial equivalence, accelerating an entire category of devices through the regulatory pipeline. The key question: what safety guardrails and ongoing monitoring requirements does the FDA attach, and do they become the template for the field?
Discussed by: Digital therapeutics industry observers, venture capital analysts tracking health technology burndown rates
The FDA's evidence requirements for generative AI prove more demanding and time-consuming than anticipated. RecovryAI's runway runs out before authorization, repeating the pattern that destroyed Pear Therapeutics and forced Woebot to shut down. The failure reinforces the narrative that FDA's device framework is structurally unsuited to software that updates and evolves, pushing generative AI health tools to operate outside the regulated medical device category — as wellness products with no clinical claims.
Discussed by: Bipartisan Policy Center, FDA regulatory scholars, Congressional health technology committees
Pressure from industry and Congress pushes the FDA to finalize its AI guidance with explicit provisions for generative AI and foundation models, potentially creating a distinct submission category or special controls for LLM-based devices. RecovryAI's review becomes part of a broader rulemaking rather than a one-off precedent. This scenario would give the industry clearer rules but could delay individual authorizations as the agency builds new infrastructure.
Discussed by: Healthcare economics researchers, Medicare coverage analysts, digital therapeutics industry groups
The FDA clears the device, but insurers decline to cover it — the same reimbursement wall that sank Pear Therapeutics and forced Akili to abandon its prescription model. Although Medicare began covering some digital mental health treatments in January 2025, coverage for post-surgical AI chatbots would require additional coding and payer buy-in. Without reimbursement, orthopedic practices have little incentive to prescribe the tool, and RecovryAI struggles to build a sustainable business despite holding FDA authorization.
Pear Therapeutics won FDA De Novo authorization for reSET, a prescription app delivering cognitive behavioral therapy for substance use disorders — the first software-only digital therapeutic the agency cleared. Pear raised over $400 million and went public via a special purpose acquisition company in 2021, positioning itself as the pioneer of a new drug-like category for software.
The clearance validated the concept that software alone could be a regulated medical device with therapeutic claims, inspiring dozens of startups to pursue similar pathways.
Pear declared bankruptcy in April 2023 after insurers largely refused to cover its products, demonstrating that FDA clearance alone cannot sustain a digital therapeutics business without a viable payment model.
RecovryAI faces the same two-stage challenge Pear encountered: first win FDA authorization, then convince payers to reimburse. The generative AI layer adds regulatory complexity Pear never faced, but Pear's collapse illustrates that clearing the FDA is only half the problem.
Woebot Health, a rules-based cognitive behavioral therapy chatbot used by more than 1.5 million people, received FDA Breakthrough Device Designation in 2021 for a postpartum depression application. The company spent years working toward full authorization. In June 2025, Woebot shut down its consumer app, with founder Alison Darcy citing the cost of FDA compliance and the agency's failure to establish a framework for the large language models the company wanted to integrate.
Woebot's closure removed one of the most prominent AI therapy tools from the consumer market, shifting its technology to enterprise-only partnerships.
The shutdown crystallized the regulatory gap: Breakthrough Device Designation offers faster review, but the underlying pathway for generative AI medical devices did not yet exist. Woebot's exit signaled that the window between technological capability and regulatory readiness could kill companies.
RecovryAI holds the same Breakthrough Device Designation that Woebot held, but is attempting what Woebot concluded was impossible — navigating FDA authorization for a product category the agency has not yet defined. RecovryAI's narrower clinical scope (30-day post-surgical recovery versus open-ended therapy) may make the regulatory task more tractable.
The FDA authorized IDx-DR (now Digital Diagnostics' LumineticsCore), the first medical device permitted to make a diagnostic decision without a physician reviewing the result. The system analyzes retinal images to detect diabetic eye disease, and a primary care provider can act on its output without referring to a specialist. The authorization came through the De Novo pathway as a Class II device.
The clearance demonstrated that the FDA could authorize autonomous AI diagnostic tools, opening a pathway that hundreds of AI medical devices would follow.
By 2025, over 1,250 AI-enabled devices had been authorized, but virtually all followed the same pattern — narrow AI analyzing structured data like medical images. The paradigm that IDx-DR established does not map neatly onto generative AI that produces novel text in conversation with patients.
IDx-DR created the regulatory precedent for AI in medicine, but it was a fundamentally different kind of AI: deterministic, narrow, and image-based. RecovryAI's generative chatbot represents a category shift that may require the FDA to rethink assumptions built on eight years of clearing image-analysis tools.
